Recent updates from the biopharmaceutical world:
- Sana Biotechnology: The company is laying off approximately one-third of its workforce and setting aside an ambitious project due to manufacturing setbacks. This is the company’s second round of layoffs in less than one year.
- NASH (Non-alcoholic Steatohepatitis) treatments: Akero Therapeutics’ NASH treatment did not meet the primary end-point in a mid-stage study, causing a 60% drop in the company’s value. This seems to have impacted the market perception of the opportunities for NASH treatments.
- Amylyx Pharmaceuticals: After being initially rejected, Amylyx has presented to European regulators for the approval of its ALS treatment. Patients with ALS were invited to the hearing, which could help sway European regulators, as previous patient involvement was a critical factor in FDA approval.
- Alnylam Pharmaceuticals: Following a surprise FDA rejection of Alnylam’s heart disease treatment, the company’s future will be influenced mainly by Phase 3 data for their injection vutrisiran, coming in early 2024. This data will determine whether the injection can be approved for ATTR-CM, a common heart disease.
To read more, click here.
[Source: STAT, October 11th, 2023]